A new drug carrier, Nα-deoxycholyl-L-lysyl-methylester, for enhancing insulin absorption in the intestine

Diabetologia

Volumn 48, Issue 3, 2005, Pages 405-411

  Lee, S ^a   Lee, J ^a   Lee, D Y ^a   Kim, S K ^a   Lee, Y ^a   Byun, Y ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Bile acid derivative; Enhancer; Insulin; Oral delivery

Indexed keywords

DEOXYCHOLIC ACID DERIVATIVE; DRUG CARRIER; ESTER DERIVATIVE; GLUCOSE; INSULIN ZINC SUSPENSION; N ALPHA DEOXYCHOLYLLYSYLMETHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INTESTINE ABSORPTION; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CHENODEOXYCHOLIC ACID; DIABETES MELLITUS, EXPERIMENTAL; DRUG CARRIERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; LYSINE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 16844365876     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1658-2     Document Type: Article

References (30)

1. Skyler JS (1986) Lessons from studies of insulin pharmacokinetics. Diabetes Care 9:666-668
2. 125I- insulin absorption and blood glucose concentration. Diabetologia 17:977-986
3. Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7:188-199
4. Owens DR (2002) New horizons - alternative routes for insulin therapy. Nat Rev Drug Discov 1:529-540
5. Cefalu WT (2004) Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 27:239-246
6. Gordberg M, Gomez-Orellana I (2003) Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 4:289-295
7. Lewis GF, Zinman B, Groenewound Y, Vranic M, Giacca A (1996) Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes 45:454-462
8. Eaton RP, Allen RC, Schade DS, Standefer JC (1980) 'Normal' insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care 3:270-273
9. Clement S, Still G, Kosutic G, McAllister RG (2002) Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 4:459-466
10. Shah RB, Ahsan F, Khan MA (2002) Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carr Syst 19:135-169
11. Sood A, Panchagnula R (2001) Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 101:3275-3303
12. Ziv E, Kidron M, Raz I et al (1994) Oral administration of insulin in solid form to nondiabetic and diabetic dogs. J Pharm Sci 83:792-794
13. Fasano A, Uzzau S (1997) Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 99:1158-1164
14. Carino GP, Mathiowitz E (1999) Oral insulin delivery. Adv Drug Deliv Rev 35:249-257
15. Mathiowitz E, Jacob JS, Jong YS et al (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410-414
16. Chung H, Kim J, Um JY, Kwon IC, Jeong SY (2002) Self-assembled 'nanocubicle' as a carrier for peroral insulin delivery. Diabetologia 45:448-451
17. Damge C, Michel C, Aprahamian M, Couvreur P (1998) New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37:246-251
18. Still JG (2002) Development of oral insulin: progress and current status. Diabetes Metab Res Rev 18:S29-S37
19. Xia CQ, Wang J, Shen WC (2000) Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 295:594-600
20. Lee Y, Nam JH, Shin HC, Byun Y (2001) Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 104:3116-3120
21. Lee Y, Kim SH, Byun Y (2000) Oral delivery of new heparin derivatives in rats. Pharm Res 17:1259-1264
22. Matern S, Gerok W (1979) Pathophysiology of the enterohepatic circulation of bile acids. Rev Physiol Biochem Pharmacol 85:125-204
23. Danilson H, Sjovall J (1985) Steroids and bile acids. Elsevier, Amsterdam
24. Kramer W, Wess G, Neckermann G et al (1994) Intestinal absorption of peptides by coupling to bile acids. J Biol Chem 269:10621-10627
25. Bowe CL, Mokhtarzadeh L, Venkatesan P et al (1997) Design of compounds that increase the absorption of polar molecules. Proc Natl Acad Sci U S A 94:12218-12223
26. Zhu XX, Nichifor M (2002) Polymeric materials containing bile acids. Acc Chem Res 35:539-546
27. Michael S, Thole M, Dillmann R, Fahr A, Drewe J, Fricker G (2000) Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci 10:133-140
28. Scott-Moncrieff JC, Shao Z, Mitra AK (1994) Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J Pharm Sci 83:1465-1469
29. Mesiha MS, Ponnapula S, Plakogiannis F (2002) Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha-tocopherol dispersions. Int J Pharm 249:1-5
30. Mosekilde E, Jensen K, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87